Hope for disease-modifying treatment of systemic sclerosis/scleroderma

Affiliations

¹ Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany; and Department of Translational Medicine and Clinical Pharmacokinetics, Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany marmiche@uni-mainz.de.

Comment

Martin C Michel. J Pharmacol Exp Ther. 2014 Sep.

. 2014 Sep;350(3):480-2.

doi: 10.1124/jpet.114.213520comm.

¹ Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany; and Department of Translational Medicine and Clinical Pharmacokinetics, Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany marmiche@uni-mainz.de.

No abstract available

Comment on

Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.
Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, Khanna D, Larsen SD, Neubig RR. Haak AJ, et al. J Pharmacol Exp Ther. 2014 Jun;349(3):480-6. doi: 10.1124/jpet.114.213520. Epub 2014 Apr 4. J Pharmacol Exp Ther. 2014. PMID: 24706986 Free PMC article.